<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02346175</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3824-103</org_study_id>
    <nct_id>NCT02346175</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK),
      safety and tolerability following single and multiple oral doses of 5mg to 20 mg SHR3824 in
      Type 2 diabetes mellitus patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters of SHR3824</measure>
    <time_frame>up to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine glucose concentration of SHR3824</measure>
    <time_frame>up to Day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma glucose concentration of SHR3824</measure>
    <time_frame>up to Day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number and type of adverse events reported</measure>
    <time_frame>Up to Day 13</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR3824</intervention_name>
    <arm_group_label>Cohort1</arm_group_label>
    <arm_group_label>Cohort2</arm_group_label>
    <arm_group_label>Cohort3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort1</arm_group_label>
    <arm_group_label>Cohort2</arm_group_label>
    <arm_group_label>Cohort3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI:20-35kg/m2;

          -  Medically stable based on physical examination, medical history, laboratory results,
             vital sign measurements, and 12-lead electrocardiogram (ECG) at screening;

          -  On a stable regimen of antihyperglycemic therapy for at least 8 weeks prior to
             screening and had fasting plasma glucose (FPG) concentration lower than 13.9 mmol/L at
             baseline;

          -  Stable antihyperglycemic regimens could include a single oral agent (eg, metformin, a
             sulfonylurea, a thiazolidinediones ketone, a benzoic acid derivatives, a dipeptidyl
             peptidase-4 inhibitor, or an Î±-glucosidase inhibitor) with glycated hemoglobin (HbA1c)
             between 7.0% and 10.0%.

        Exclusion Criteria:

          -  History of clinically significant diabetic complications, type 1 diabetes mellitus, or
             repeated severe hypoglycemic episodes.

          -  Pregnancy or breastfeeding;

          -  Significant acute or chronic medical illness, including renal impairment, or recent
             surgery;

          -  Donation of blood or plasma within the 4 weeks prior to the start of the study;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>February 1, 2015</last_update_submitted>
  <last_update_submitted_qc>February 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR3824 Type 2 diabetes mellitus SGLT2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

